Progyny, Inc. (PGNY) Downgraded to Equal-Weight by Barclays

Market Context

Progyny, Inc. operates in the Healthcare sector. The stock currently trades at $30.76 with a market capitalization of $2.2B.

Analyst downgrades can weigh on a stock in the short term as institutional investors who follow Barclays's research adjust their positions. However, downgrades also sometimes create buying opportunities if the market overreacts to the rating change. The reasoning behind the downgrade matters more than the rating itself.

Analyst ratings and price targets are one input among many for investment decisions. Historical studies show that consensus analyst recommendations have mixed predictive power on their own, but significant changes in consensus — such as multiple upgrades or downgrades in a short period — can be more meaningful signals.

Recent Analyst Activity for Progyny, Inc.

Among the 10 most recent ratings: 9 Buy, 1 Hold, 0 Sell.

Date	Firm	Rating	Price Target
Jul 28, 2026	Barclays	Equal-Weight	N/A
Jul 24, 2026	BTIG	Buy	N/A
Jul 21, 2026	Canaccord Genuity	Buy	N/A
Jul 13, 2026	Keybanc	Overweight	N/A
Jun 22, 2026	Truist Securities	Buy	N/A

Related Tools: Analyst Ratings Dashboard | View PGNY Stock Page